HDAC-IN-30
HDAC-IN-30 is a novel multi-target HDAC inhibitor, including HDAC1 (IC50=13.4 nM), HDAC2 (IC50=28.0 nM), HDAC3 (IC50=9.18 nM), HDAC6 (IC50=42.7 nM), HDAC8 (IC50=131 nM) . HDAC-IN-30 exhibits potent antitumor efficacy[1].
Product Specifications
CAS Number
2756809-34-2
UNSPSC
12352209
Target
HDAC
Type
Peptides
Related Pathways
Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/hdac-in-30.html
Solubility
10 mM in DMSO
Smiles
O=C(NO)CCCCCCNC(C1=C2C=CC=C1)=NN3C2=NC4=C(C=CC=C4)C3=O
Molecular Formula
C22H23N5O3
Molecular Weight
405.45
References & Citations
[1]Liu Q, et al. Discovery of phthalazino [1, 2-b]-quinazolinone derivatives as multi-target HDAC inhibitors for the treatment of hepatocellular carcinoma via activating the p53 signal pathway. Eur J Med Chem. 2022, 229:114058.
Shipping Conditions
Room temperature
Scientific Category
Peptides
Clinical Information
No Development Reported
Isoform
HDAC1; HDAC2; HDAC3; HDAC6; HDAC8
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog